| NCT03190265 |
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer |
View |
| NCT03817866 |
Chromogranin A as Blood Marker in Cancer Patients |
View |
| NCT06316466 |
Lipoprotein a is an Independent Risk Factor for Overall Survival in Patients With Pancreatic Cancer: a Propensity Score Matching Analysis |
View |
| NCT00338026 |
A Phase I Study of ECO-4601 in Patients With Advanced Cancer |
View |
| NCT02576665 |
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) |
View |
| NCT03099265 |
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma |
View |
| NCT05475366 |
Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures |
View |
| NCT02720666 |
K-001 Treatment of Advanced Pancreatic Cancer: Clinical Trial of Monotherapy's Tolerability |
View |
| NCT06199466 |
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer |
View |
| NCT04391426 |
Analysis of Biliary Microbiota in Hepatobiliopancreatic Diseases Compared to Healthy People [MICROBILIO] |
View |
| NCT00059826 |
Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer |
View |
| NCT01010126 |
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer |
View |
| NCT05874726 |
Biological Sample Repository for Gastrointestinal Disorders |
View |
| NCT02528526 |
Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm |
View |
| NCT03251365 |
Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer |
View |
| NCT07021066 |
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors |
View |
| NCT02822066 |
Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas |
View |
| NCT05825066 |
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma |
View |
| NCT00907166 |
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients |
View |
| NCT02433626 |
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies |
View |
| NCT06390826 |
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) |
View |
| NCT04212026 |
Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer. |
View |
| NCT05968326 |
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC |
View |
| NCT05336266 |
A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma |
View |
| NCT00515866 |
Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer |
View |
